Identification

Name
Nandrolone decanoate
Accession Number
DB08804
Type
Small Molecule
Groups
Approved, Illicit
Description

C18 steroid with androgenic and anabolic properties. It is generally prepared from alkyl ethers of estradiol to resemble testosterone but less one carbon at the 19 position. It is a schedule III drug in the U.S.

Structure
Thumb
Synonyms
  • 19-nortestosterone decanoate
  • Nandrolone 17β-decanoate
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Deca Durabolin Inj 100mg/mlSolution100 mgIntramuscularSchering Plough1973-12-312010-07-26Canada
Deca Durabolin Inj 50mg/mlLiquid50 mgIntramuscularOrganon Canada Ltd Ltee1973-12-311996-09-10Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nandrolone DecanoateInjection, solution200 mg/mLIntramuscularAmerican Regent2000-01-01Not applicableUs
International/Other Brands
Deca-Durabol / Deca-Durabolin / Retabolil
Categories
UNII
H45187T098
CAS number
360-70-3
Weight
Average: 428.6472
Monoisotopic: 428.329045274
Chemical Formula
C28H44O3
InChI Key
JKWKMORAXJQQSR-MOPIKTETSA-N
InChI
InChI=1S/C28H44O3/c1-3-4-5-6-7-8-9-10-27(30)31-26-16-15-25-24-13-11-20-19-21(29)12-14-22(20)23(24)17-18-28(25,26)2/h19,22-26H,3-18H2,1-2H3/t22-,23+,24+,25-,26-,28-/m0/s1
IUPAC Name
(1S,2R,10R,11S,14S,15S)-15-methyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl decanoate
SMILES

Pharmacology

Indication

For the treatment of refractory deficient red cell production anemias, breast carcinoma, hereditary angioedema, antithrombin III deficiency, fibrinogen excess, growth failure and Turner's syndrome. It is also indicated in the prophylaxis of hereditary angioedema.

Structured Indications
Pharmacodynamics

Nandrolone is an anabolic steroid occurring naturally in the human body, albeit in small quantities. Nandrolone increases production and urinary excretion of erythropoietin. It may also have a direct action on bone marrow. Nandrolone binds to the androgen receptor to a greater degree than testosterone, but due to its inability to act on the muscle in ways unmediated by the receptor, has less overall effect on muscle growth.

Mechanism of action

Nandrolone is an androgen receptor agonist. The drug bound to the receptor complexes which allows it to enter the nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects.

TargetActionsOrganism
AAndrogen receptor
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

58%

Metabolism

Nandrolone is unusual in that unlike most anabolic steroids, it is not broken down into the more reactive DHT by the enzyme 5α-reductase, but rather into a less effective product known as Dihydronandrolone.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the fluid retaining activities of Nandrolone decanoate.Investigational
19-norandrostenedione19-norandrostenedione may increase the fluid retaining activities of Nandrolone decanoate.Experimental, Illicit
5-androstenedione5-androstenedione may increase the fluid retaining activities of Nandrolone decanoate.Experimental, Illicit
AcarboseNandrolone decanoate may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcenocoumarolNandrolone decanoate may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AlbiglutideNandrolone decanoate may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneAlclometasone may increase the fluid retaining activities of Nandrolone decanoate.Approved
AldosteroneAldosterone may increase the fluid retaining activities of Nandrolone decanoate.Experimental, Investigational
AlogliptinNandrolone decanoate may increase the hypoglycemic activities of Alogliptin.Approved
AmcinonideAmcinonide may increase the fluid retaining activities of Nandrolone decanoate.Approved
AndrostenedioneAndrostenedione may increase the fluid retaining activities of Nandrolone decanoate.Experimental, Illicit
AnecortaveAnecortave may increase the fluid retaining activities of Nandrolone decanoate.Investigational
anecortave acetateanecortave acetate may increase the fluid retaining activities of Nandrolone decanoate.Investigational
AtamestaneAtamestane may increase the fluid retaining activities of Nandrolone decanoate.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the fluid retaining activities of Nandrolone decanoate.Approved, Investigational
BetamethasoneBetamethasone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Vet Approved
BromocriptineNandrolone decanoate may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BudesonideBudesonide may increase the fluid retaining activities of Nandrolone decanoate.Approved
CanagliflozinNandrolone decanoate may increase the hypoglycemic activities of Canagliflozin.Approved
ChlorpropamideNandrolone decanoate may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
CiclesonideCiclesonide may increase the fluid retaining activities of Nandrolone decanoate.Approved, Investigational
ClobetasolClobetasol may increase the fluid retaining activities of Nandrolone decanoate.Approved, Investigational
Clobetasol propionateClobetasol propionate may increase the fluid retaining activities of Nandrolone decanoate.Approved
ClobetasoneClobetasone may increase the fluid retaining activities of Nandrolone decanoate.Approved
ClocortoloneClocortolone may increase the fluid retaining activities of Nandrolone decanoate.Approved
ClorindioneNandrolone decanoate may increase the anticoagulant activities of Clorindione.Experimental
Conestat alfaNandrolone decanoate may increase the thrombogenic activities of Conestat alfa.Approved, Investigational
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the fluid retaining activities of Nandrolone decanoate.Investigational
CorticosteroneCorticosterone may increase the fluid retaining activities of Nandrolone decanoate.Experimental
Cortisone acetateCortisone acetate may increase the fluid retaining activities of Nandrolone decanoate.Approved, Investigational
CyclosporineNandrolone decanoate may increase the hepatotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
DapagliflozinNandrolone decanoate may increase the hypoglycemic activities of Dapagliflozin.Approved
Darbepoetin alfaNandrolone decanoate may increase the stimulatory activities of Darbepoetin alfa.Approved, Investigational
DeflazacortDeflazacort may increase the fluid retaining activities of Nandrolone decanoate.Approved, Investigational
DesonideDesonide may increase the fluid retaining activities of Nandrolone decanoate.Approved, Investigational
DesoximetasoneDesoximetasone may increase the fluid retaining activities of Nandrolone decanoate.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the fluid retaining activities of Nandrolone decanoate.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the fluid retaining activities of Nandrolone decanoate.Experimental, Vet Approved
DexamethasoneDexamethasone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the fluid retaining activities of Nandrolone decanoate.Vet Approved
DicoumarolNandrolone decanoate may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneDiflorasone may increase the fluid retaining activities of Nandrolone decanoate.Approved
DifluocortoloneDifluocortolone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Investigational, Withdrawn
DifluprednateDifluprednate may increase the fluid retaining activities of Nandrolone decanoate.Approved
DiphenadioneNandrolone decanoate may increase the anticoagulant activities of Diphenadione.Experimental
DisopyramideNandrolone decanoate may increase the hypoglycemic activities of Disopyramide.Approved
DulaglutideNandrolone decanoate may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
EmpagliflozinNandrolone decanoate may increase the hypoglycemic activities of Empagliflozin.Approved
EquileninEquilenin may increase the fluid retaining activities of Nandrolone decanoate.Experimental
EquilinEquilin may increase the fluid retaining activities of Nandrolone decanoate.Approved
ErythropoietinNandrolone decanoate may increase the stimulatory activities of Erythropoietin.Approved
EstroneEstrone may increase the fluid retaining activities of Nandrolone decanoate.Approved
Estrone sulfateEstrone sulfate may increase the fluid retaining activities of Nandrolone decanoate.Approved
Ethyl biscoumacetateNandrolone decanoate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
ExenatideNandrolone decanoate may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FluasteroneFluasterone may increase the fluid retaining activities of Nandrolone decanoate.Investigational
FludrocortisoneFludrocortisone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Investigational
FluindioneNandrolone decanoate may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneFlumethasone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Vet Approved
FlunisolideFlunisolide may increase the fluid retaining activities of Nandrolone decanoate.Approved, Investigational
Fluocinolone AcetonideFluocinolone Acetonide may increase the fluid retaining activities of Nandrolone decanoate.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the fluid retaining activities of Nandrolone decanoate.Approved, Investigational
FluocortoloneFluocortolone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Withdrawn
FluorometholoneFluorometholone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Investigational
FluprednideneFluprednidene may increase the fluid retaining activities of Nandrolone decanoate.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the fluid retaining activities of Nandrolone decanoate.Approved
FlurandrenolideFlurandrenolide may increase the fluid retaining activities of Nandrolone decanoate.Approved
Fluticasone furoateFluticasone furoate may increase the fluid retaining activities of Nandrolone decanoate.Approved
Fluticasone propionateFluticasone propionate may increase the fluid retaining activities of Nandrolone decanoate.Approved
FormestaneFormestane may increase the fluid retaining activities of Nandrolone decanoate.Approved, Investigational, Withdrawn
GliclazideNandrolone decanoate may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideNandrolone decanoate may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideNandrolone decanoate may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideNandrolone decanoate may increase the hypoglycemic activities of Glyburide.Approved
HalcinonideHalcinonide may increase the fluid retaining activities of Nandrolone decanoate.Approved, Investigational, Withdrawn
HE3286HE3286 may increase the fluid retaining activities of Nandrolone decanoate.Investigational
Human C1-esterase inhibitorNandrolone decanoate may increase the thrombogenic activities of Human C1-esterase inhibitor.Approved
HydrocortisoneHydrocortisone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Vet Approved
Insulin AspartNandrolone decanoate may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirNandrolone decanoate may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineNandrolone decanoate may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineNandrolone decanoate may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanNandrolone decanoate may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproNandrolone decanoate may increase the hypoglycemic activities of Insulin Lispro.Approved
IstaroximeIstaroxime may increase the fluid retaining activities of Nandrolone decanoate.Investigational
LiraglutideNandrolone decanoate may increase the hypoglycemic activities of Liraglutide.Approved
LoteprednolLoteprednol may increase the fluid retaining activities of Nandrolone decanoate.Approved
ME-609ME-609 may increase the fluid retaining activities of Nandrolone decanoate.Investigational
MecaserminNandrolone decanoate may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MedrysoneMedrysone may increase the fluid retaining activities of Nandrolone decanoate.Approved
MelengestrolMelengestrol may increase the fluid retaining activities of Nandrolone decanoate.Vet Approved
MetforminNandrolone decanoate may increase the hypoglycemic activities of Metformin.Approved
Methoxy polyethylene glycol-epoetin betaNandrolone decanoate may increase the stimulatory activities of Methoxy polyethylene glycol-epoetin beta.Approved
MethylprednisoloneMethylprednisolone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Vet Approved
MifepristoneNandrolone decanoate may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolNandrolone decanoate may increase the hypoglycemic activities of Miglitol.Approved
MometasoneMometasone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Vet Approved
NateglinideNandrolone decanoate may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022NCX 1022 may increase the fluid retaining activities of Nandrolone decanoate.Investigational
Oleoyl-estroneOleoyl-estrone may increase the fluid retaining activities of Nandrolone decanoate.Investigational
ParamethasoneParamethasone may increase the fluid retaining activities of Nandrolone decanoate.Approved
PentamidineNandrolone decanoate may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PhenindioneNandrolone decanoate may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonNandrolone decanoate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PioglitazoneNandrolone decanoate may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PramlintideNandrolone decanoate may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteronePrasterone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Investigational, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the fluid retaining activities of Nandrolone decanoate.Investigational
PrednicarbatePrednicarbate may increase the fluid retaining activities of Nandrolone decanoate.Approved, Investigational
PrednisolonePrednisolone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Vet Approved
PrednisonePrednisone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Vet Approved
PregnenolonePregnenolone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Experimental, Investigational
QuinineNandrolone decanoate may increase the hypoglycemic activities of Quinine.Approved
RepaglinideNandrolone decanoate may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RimexoloneRimexolone may increase the fluid retaining activities of Nandrolone decanoate.Approved
RosiglitazoneNandrolone decanoate may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SaxagliptinNandrolone decanoate may increase the hypoglycemic activities of Saxagliptin.Approved
SitagliptinNandrolone decanoate may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SulfadiazineNandrolone decanoate may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleNandrolone decanoate may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleNandrolone decanoate may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SunitinibNandrolone decanoate may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TioclomarolNandrolone decanoate may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolTixocortol may increase the fluid retaining activities of Nandrolone decanoate.Approved, Withdrawn
TolazamideNandrolone decanoate may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideNandrolone decanoate may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TriamcinoloneTriamcinolone may increase the fluid retaining activities of Nandrolone decanoate.Approved, Vet Approved
UlobetasolUlobetasol may increase the fluid retaining activities of Nandrolone decanoate.Approved
WarfarinNandrolone decanoate may increase the anticoagulant activities of Warfarin.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0015694
KEGG Drug
D00955
KEGG Compound
C08154
PubChem Compound
9677
PubChem Substance
99445274
ChemSpider
9296
ChEBI
7467
ChEMBL
CHEMBL1200946
Therapeutic Targets Database
DAP000903
PharmGKB
PA165958423
Drugs.com
Drugs.com Drug Page
Wikipedia
Nandrolone_decanoate
MSDS
Download (49.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHIV Wasting Syndrome / Human Immunodeficiency Virus (HIV) Infections1
1, 2RecruitingTreatmentAplastic Anaemia (AA) / Bone Marrow Failure Syndromes / Idiopathic Pulmonary Fibrosis (IPF) / Telomere Shortening1
Not AvailableCompletedTreatmentEnd-Stage Renal Disease (ESRD) / Muscle Weakness1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SolutionIntramuscular100 mg
LiquidIntramuscular50 mg
Injection, solutionIntramuscular200 mg/mL
Prices
Unit descriptionCostUnit
Deca-Durabolin 100 mg/ml97.16USD ml
Nandrolone decanoate powder79.88USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)118 °CNot Available
water solubility3.09 mg/mL at 25 °CYALKOWSKY,SH & HE,Y (2003)
logP2.62HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.000157 mg/mLALOGPS
logP5.96ALOGPS
logP7.32ChemAxon
logS-6.4ALOGPS
pKa (Strongest Acidic)19.28ChemAxon
pKa (Strongest Basic)-4.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area43.37 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity125.94 m3·mol-1ChemAxon
Polarizability53.65 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.97
Caco-2 permeable+0.6718
P-glycoprotein substrateSubstrate0.6327
P-glycoprotein inhibitor IInhibitor0.8364
P-glycoprotein inhibitor IIInhibitor0.5069
Renal organic cation transporterNon-inhibitor0.7532
CYP450 2C9 substrateNon-substrate0.8741
CYP450 2D6 substrateNon-substrate0.9285
CYP450 3A4 substrateSubstrate0.72
CYP450 1A2 substrateNon-inhibitor0.94
CYP450 2C9 inhibitorNon-inhibitor0.8841
CYP450 2D6 inhibitorNon-inhibitor0.9111
CYP450 2C19 inhibitorNon-inhibitor0.5353
CYP450 3A4 inhibitorNon-inhibitor0.7896
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5493
Ames testNon AMES toxic0.9431
CarcinogenicityNon-carcinogens0.9215
BiodegradationNot ready biodegradable0.9625
Rat acute toxicity1.8804 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8573
hERG inhibition (predictor II)Non-inhibitor0.7636
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Steroid esters
Direct Parent
Steroid esters
Alternative Parents
Estrogens and derivatives / 3-oxo delta-4-steroids / Delta-4-steroids / Cyclohexenones / Carboxylic acid esters / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives
Substituents
Steroid ester / Estrogen-skeleton / 3-oxo-delta-4-steroid / 3-oxosteroid / Oxosteroid / Estrane-skeleton / Delta-4-steroid / Cyclohexenone / Carboxylic acid ester / Cyclic ketone
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
steroid ester (CHEBI:7467)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
Gene Name
AR
Uniprot ID
P10275
Uniprot Name
Androgen receptor
Molecular Weight
98987.9 Da
References
  1. Birgner C, Kindlundh-Hogberg AM, Alsio J, Lindblom J, Schioth HB, Bergstrom L: The anabolic androgenic steroid nandrolone decanoate affects mRNA expression of dopaminergic but not serotonergic receptors. Brain Res. 2008 Nov 13;1240:221-8. doi: 10.1016/j.brainres.2008.09.003. Epub 2008 Sep 13. [PubMed:18809391]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Takahashi K, Hallberg M, Magnusson K, Nyberg F, Watanabe Y, Langstrom B, Bergstrom M: Increase in [11C]vorozole binding to aromatase in the hypothalamus in rats treated with anabolic androgenic steroids. Neuroreport. 2007 Jan 22;18(2):171-4. [PubMed:17301684]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Primary amine oxidase activity
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOB
Uniprot ID
P27338
Uniprot Name
Amine oxidase [flavin-containing] B
Molecular Weight
58762.475 Da
References
  1. Birgner C, Kindlundh-Hogberg AM, Oreland L, Alsio J, Lindblom J, Schioth HB, Bergstrom L: Reduced activity of monoamine oxidase in the rat brain following repeated nandrolone decanoate administration. Brain Res. 2008 Jul 11;1219:103-10. doi: 10.1016/j.brainres.2008.05.014. Epub 2008 May 17. [PubMed:18539264]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Birgner C, Kindlundh-Hogberg AM, Oreland L, Alsio J, Lindblom J, Schioth HB, Bergstrom L: Reduced activity of monoamine oxidase in the rat brain following repeated nandrolone decanoate administration. Brain Res. 2008 Jul 11;1219:103-10. doi: 10.1016/j.brainres.2008.05.014. Epub 2008 May 17. [PubMed:18539264]

Drug created on June 13, 2005 07:24 / Updated on March 02, 2018 03:42